Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
02 07 2019
Historique:
pubmed: 19 6 2019
medline: 9 4 2020
entrez: 19 6 2019
Statut: ppublish

Résumé

Cyclic AMP (cAMP) phosphodiesterase-4 (PDE4) enzymes degrade cAMP and underpin the compartmentalization of cAMP signaling through their targeting to particular protein complexes and intracellular locales. We describe the discovery and characterization of a small-molecule compound that allosterically activates PDE4 long isoforms. This PDE4-specific activator displays reversible, noncompetitive kinetics of activation (increased

Identifiants

pubmed: 31209056
pii: 1822113116
doi: 10.1073/pnas.1822113116
pmc: PMC6613170
doi:

Substances chimiques

Protein Isoforms 0
Cyclic AMP E0399OZS9N
Cyclic AMP-Dependent Protein Kinases EC 2.7.11.11
Cyclic Nucleotide Phosphodiesterases, Type 4 EC 3.1.4.17

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

13320-13329

Informations de copyright

Copyright © 2019 the Author(s). Published by PNAS.

Déclaration de conflit d'intérêts

Conflict of interest statement: D.J.P.H., F.O., J.E.F., R.W.A., Z.J., G.C., C.M., A.L.M., K.B., J.M.A., D.R.A., and M.D.H. are employees of Mironid, Limited. N.J.P., E.K., and A.C.M.O. act as consultants to Mironid, Limited.

Références

EMBO J. 1999 Feb 15;18(4):893-903
pubmed: 10022832
J Biol Chem. 1999 Apr 23;274(17):11796-810
pubmed: 10206997
Mol Biol Cell. 1999 Dec;10(12):4355-67
pubmed: 10588663
J Biol Chem. 2000 Apr 7;275(14):10349-58
pubmed: 10744723
J Biol Chem. 2000 Apr 14;275(15):10831-7
pubmed: 10753877
Br J Pharmacol. 2000 Oct;131(4):811-9
pubmed: 11030732
Prog Nucleic Acid Res Mol Biol. 2001;69:249-315
pubmed: 11550796
Mol Pharmacol. 2001 Nov;60(5):1100-11
pubmed: 11641439
J Am Soc Nephrol. 2002 Mar;13(3):595-603
pubmed: 11856762
Br J Pharmacol. 2002 Jun;136(3):421-33
pubmed: 12023945
J Neurochem. 2002 May;81(4):745-57
pubmed: 12065634
J Biol Chem. 2002 Sep 27;277(39):35980-9
pubmed: 12121997
J Biol Chem. 2002 Oct 25;277(43):40212-21
pubmed: 12177055
FEBS Lett. 2002 Oct 23;530(1-3):53-8
pubmed: 12387865
Biochem J. 2003 Feb 15;370(Pt 1):1-18
pubmed: 12444918
J Biol Chem. 2003 Feb 21;278(8):5493-6
pubmed: 12493749
J Pharmacol Exp Ther. 2003 May;305(2):565-72
pubmed: 12704225
Physiol Rev. 2004 Jan;84(1):137-67
pubmed: 14715913
J Biol Chem. 2004 Jul 16;279(29):30338-48
pubmed: 15131123
Kidney Int. 2004 Nov;66(5):1926-38
pubmed: 15496164
J Biol Chem. 2005 Sep 30;280(39):33178-89
pubmed: 16030021
Drug Discov Today. 2005 Nov 15;10(22):1503-19
pubmed: 16257373
Biochem J. 2006 Jan 1;393(Pt 1):21-41
pubmed: 16336197
Psychopharmacology (Berl). 2006 Jun;186(2):209-17
pubmed: 16586089
Kidney Int. 2007 Jul;72(2):157-65
pubmed: 17396115
Circ Res. 2007 Apr 13;100(7):950-66
pubmed: 17431197
J Biol Chem. 2007 Nov 23;282(47):34235-49
pubmed: 17855344
J Am Soc Nephrol. 2008 Jul;19(7):1300-10
pubmed: 18385427
Trends Biochem Sci. 2010 Feb;35(2):91-100
pubmed: 19864144
Curr Pharm Des. 2010;16(9):1114-25
pubmed: 20030615
Nat Biotechnol. 2010 Jan;28(1):63-70
pubmed: 20037581
Nat Biotechnol. 2010 Jan;28(1):38-40
pubmed: 20062038
Biochim Biophys Acta. 2011 Oct;1812(10):1291-300
pubmed: 21118718
J Mol Med (Berl). 2011 Mar;89(3):251-61
pubmed: 21206992
Biochim Biophys Acta. 2011 Oct;1812(10):1314-21
pubmed: 21255645
Biochem J. 2011 May 1;435(3):755-69
pubmed: 21323643
J Med Chem. 2011 May 12;54(9):3331-47
pubmed: 21456625
Physiol Rev. 2011 Apr;91(2):651-90
pubmed: 21527734
Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10679-84
pubmed: 21670265
Handb Exp Pharmacol. 2011;(204):391-414
pubmed: 21695650
Chang Gung Med J. 2012 May-Jun;35(3):197-210
pubmed: 22735051
Pharmacol Rev. 2013 Feb 27;65(2):670-709
pubmed: 23447132
J Biomol Screen. 2013 Oct;18(9):1132-7
pubmed: 23653393
Am J Respir Cell Mol Biol. 2014 Mar;50(3):549-58
pubmed: 24106801
J Am Soc Nephrol. 2014 Feb;25(2):232-7
pubmed: 24158982
FASEB J. 2014 Feb;28(2):791-801
pubmed: 24200884
J Am Soc Nephrol. 2014 Jan;25(1):18-32
pubmed: 24335972
Br J Pharmacol. 2014 May;171(9):2385-98
pubmed: 24467222
Br J Cancer. 2014 Mar 4;110(5):1278-87
pubmed: 24518597
Biochem J. 2014 May 1;459(3):539-50
pubmed: 24555506
Pflugers Arch. 1988 Apr;411(4):450-5
pubmed: 2456518
Nat Rev Drug Discov. 2014 Apr;13(4):290-314
pubmed: 24687066
Proc Natl Acad Sci U S A. 1989 Aug;86(15):6007-11
pubmed: 2474825
Cell Signal. 2015 Apr;27(4):756-69
pubmed: 25546709
Cell Signal. 2015 May;27(5):908-22
pubmed: 25683917
Trends Pharmacol Sci. 2015 Apr;36(4):203-14
pubmed: 25744542
Proc Natl Acad Sci U S A. 2015 Mar 24;112(12):E1414-22
pubmed: 25775568
Nat Rev Nephrol. 2015 Aug;11(8):451-64
pubmed: 25870007
Curr Drug Targets. 2017;18(8):950-957
pubmed: 25915482
Lancet. 2015 May 16;385(9981):1993-2002
pubmed: 26090645
Kidney Int. 2015 Oct;88(4):699-710
pubmed: 26200945
J Am Soc Nephrol. 2016 Apr;27(4):1124-34
pubmed: 26289612
Cell Signal. 2016 Jul;28(7):719-24
pubmed: 26562185
Prog Biophys Mol Biol. 2016 Jan;120(1-3):28-36
pubmed: 26772438
Am J Physiol Renal Physiol. 2017 Apr 1;312(4):F577-F588
pubmed: 28077374
Kidney Int. 2018 Feb;93(2):403-415
pubmed: 29042084
Biochem J. 1980 May 1;187(2):381-92
pubmed: 6249268
Mol Pharmacol. 1995 Oct;48(4):616-22
pubmed: 7476886
J Pharmacol Exp Ther. 1995 Jun;273(3):1396-402
pubmed: 7791113
J Biol Chem. 1996 Jul 12;271(28):16526-34
pubmed: 8663227
Mol Pharmacol. 1997 Feb;51(2):242-9
pubmed: 9203629
Cell Signal. 1997 May-Jun;9(3-4):227-36
pubmed: 9218122
Biochem J. 1997 Dec 1;328 ( Pt 2):539-48
pubmed: 9371713
J Pharmacol Exp Ther. 1998 Jan;284(1):420-6
pubmed: 9435206
Biochem J. 1998 Jul 1;333 ( Pt 1):139-49
pubmed: 9639573

Auteurs

Faisa Omar (F)

Mironid, Ltd., Newhouse, North Lanarkshire ML1 5UH, Scotland, United Kingdom.

Jane E Findlay (JE)

Mironid, Ltd., Newhouse, North Lanarkshire ML1 5UH, Scotland, United Kingdom.

Gemma Carfray (G)

Mironid, Ltd., Newhouse, North Lanarkshire ML1 5UH, Scotland, United Kingdom.

Robert W Allcock (RW)

Mironid, Ltd., Newhouse, North Lanarkshire ML1 5UH, Scotland, United Kingdom.
Institute of Chemical Sciences, Heriot-Watt University, Edinburgh EH14 4AS, United Kingdom.

Zhong Jiang (Z)

Mironid, Ltd., Newhouse, North Lanarkshire ML1 5UH, Scotland, United Kingdom.
Institute of Chemical Sciences, Heriot-Watt University, Edinburgh EH14 4AS, United Kingdom.

Caitlin Moore (C)

Mironid, Ltd., Newhouse, North Lanarkshire ML1 5UH, Scotland, United Kingdom.

Amy L Muir (AL)

Mironid, Ltd., Newhouse, North Lanarkshire ML1 5UH, Scotland, United Kingdom.

Morgane Lannoy (M)

Academic Nephrology Unit, Department of Infection Immunity and Cardiovascular Disease, University of Sheffield Medical School, Sheffield S10 2RX, United Kingdom.

Bracy A Fertig (BA)

Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow G12 8QQ, United Kingdom.

Deborah Mai (D)

DiscoveryBioMed, Inc., Birmingham, AL 35242.

Jonathan P Day (JP)

Department of Genetics, University of Cambridge, CB2 3EH Cambridge, United Kingdom.

Graeme Bolger (G)

Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294-3300.

George S Baillie (GS)

Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow G12 8QQ, United Kingdom.

Erik Schwiebert (E)

DiscoveryBioMed, Inc., Birmingham, AL 35242.

Enno Klussmann (E)

Max-Delbrück-Centrum für Molekulare Medizin, 13092 Berlin, Germany.
Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institut für Vegetative Physiologie, 10117 Berlin, Germany.

Nigel J Pyne (NJ)

Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G1 1XQ, Scotland, United Kingdom.

Albert C M Ong (ACM)

Academic Nephrology Unit, Department of Infection Immunity and Cardiovascular Disease, University of Sheffield Medical School, Sheffield S10 2RX, United Kingdom.

Keith Bowers (K)

Mironid, Ltd., Newhouse, North Lanarkshire ML1 5UH, Scotland, United Kingdom.
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G1 1XQ, Scotland, United Kingdom.

Julia M Adam (JM)

Mironid, Ltd., Newhouse, North Lanarkshire ML1 5UH, Scotland, United Kingdom.

David R Adams (DR)

Mironid, Ltd., Newhouse, North Lanarkshire ML1 5UH, Scotland, United Kingdom.
Institute of Chemical Sciences, Heriot-Watt University, Edinburgh EH14 4AS, United Kingdom.

Miles D Houslay (MD)

Mironid, Ltd., Newhouse, North Lanarkshire ML1 5UH, Scotland, United Kingdom.
School of Cancer and Pharmaceutical Sciences, King's College London, London SE1 9NH, United Kingdom.

David J P Henderson (DJP)

Mironid, Ltd., Newhouse, North Lanarkshire ML1 5UH, Scotland, United Kingdom; david.henderson@mironid.com.
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G1 1XQ, Scotland, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH